Is HSIC a good stock to buy right now?

Based on our 6-factor quantitative model, HENRY SCHEIN INC (HSIC) receives a "Hold" rating with a composite score of 47.4/100. It is ranked #1,458 out of 4,446 stocks. Key factor scores: Quality 50/100, Value 48/100, Momentum 49/100. The timing signal is "Neutral". This is quantitative analysis only — not investment advice.

What is the stock rating for HSIC?

HENRY SCHEIN INC (HSIC) has a "Hold" rating and 3-star score. The composite score of 47.4 ranks it #1,458 among 4,446 U.S. stocks. Ratings are updated weekly using academically-proven factor models.

What sector is HSIC in?

HENRY SCHEIN INC operates in the Consumer Staples sector (Wholesale industry) with a market cap of $8.38 billion. It is classified as a mid-cap stock.

Does HSIC pay a dividend?

HSIC does not currently pay a regular dividend. The company may be reinvesting profits for growth.

What is HSIC's P/E ratio?

HSIC has a trailing P/E ratio of 20.41x. The Consumer Staples sector average is 33.1x. This P/E is in a moderate range relative to the broader market.

How profitable is HSIC?

HSIC's quality factor score is 50/100. Gross margin: 31.2%. ROE: 10.3% vs sector average 7.7%. Margins are moderate to low, reflecting competitive market dynamics.

How is HSIC valued compared to peers?

HSIC's value factor score is 48/100 (higher = cheaper). Key multiples: P/E 20.4x, EV/EBITDA 9.4x. Valuation is roughly in line with peers.

What is HSIC's debt level?

HSIC's debt-to-equity ratio is 154%. Sector average: 72%. Elevated leverage increases credit risk.

HSIC has a beta of 0.64, meaning it is less volatile than the market. Stability score: 83/100.

Does HSIC have high short interest?

HSIC's short interest factor score is 16/100 (higher = less short selling). Elevated short interest may indicate bearish sentiment or short squeeze potential.

HSIC Stock Analysis: Top Mid-Cap Hold (Score 47.4/100) | Blank Capital Research

Data Series	1D	5D	1M	YTD	1Y	3Y	5Y	10Y
HSIC	-0.37%	+1.89%	-1.25%	-0.32%	+18.53%	-	-	-
Industry Proxy XLP	-1.29%	+0.59%	-3.91%	+6.04%	+3.81%	-	-	-
U.S. Market SPY	-0.07%	+3.60%	+0.34%	-0.36%	+29.52%	-	-	-
Alpha vs Market	-0.30%	-1.71%	-1.58%	+0.04%	-10.99%	-	-	-
Alpha vs Sector	+0.92%	+1.31%	+2.66%	-6.36%	+14.73%	-	-	-

Metric	HSIC	Benchmark
P/E Ratio	20.4x	-38%
EV/EBITDA	9.4x	+35%
Price / Book	2.1x

Stock Entity	Score▼	Quality	Value	Momentum	P/E Ratio	ROE	Gross Margin	Net Margin	Rev Growth	D/E Ratio	Market Cap	Compare
ITRN Ituran Location & Control Ltd.	60	48	82	70	19.6x	122.1%	47.8%	16.8%	-	0.0x	$1.0B	VS
SENEA Seneca Foods Corp	55	49	59	69	10.3x	14.4%	14.3%	6.7%	70.9%	39.0x	$1.1B	VS
JBSS SANFILIPPO JOHN B & SON INC	54	50	57	61	12.8x	20.2%	19.3%	6.3%	14.0%	11.0x	$965M	VS
ARW ARROW ELECTRONICS, INC.	53	50	73	63	15.8x	7.2%	11.2%	1.6%	11.9%	337.0x	$7.5B	VS
SFD SMITHFIELD FOODS INC	53	50	72	57	13.8x	11.9%	19.9%	7.5%	7.3%	29.0x	$11.3B	VS
BG Bunge Global SA	53	50	54	69	24.9x	5.7%	5.4%	1.8%	67.3%	59.0x	$24.8B	VS
DAR DARLING INGREDIENTS INC.	53	50	55	71	142.7x	1.5%	24.1%	1.2%	13.3%	114.0x	$9.9B	VS
ADM Archer-Daniels-Midland Co	52	50	52	64	54.6x	2.8%	6.4%	0.8%	-8.4%	33.0x	$34.9B	VS
CTVA Corteva, Inc.	52	49	51	60	50.6x	4.7%	42.9%	0.2%	-57.2%	76.0x	$56.3B	VS
MO ALTRIA GROUP, INC.	51	50	67	51	13.6x	-	62.1%	33.8%	-2.2%	-990.0x	$109.5B	VS
HSIC HENRY SCHEIN INC	47	50	48	49	20.4x	10.3%	31.2%	3.2%	6.5%	154.0x	$8.4B

Key Ratio	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016
Gross Margin %	0.3%	0.3%	0.3%	0.3%	0.3%	0.3%	0.3%	0.3%	0.3%	0.3%	0.3%
Operating Margin %	0.1%	0.0%	0.0%	0.0%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%
EBITDA Margin %	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%
Net Margin %	0.0%	0.0%	0.0%	0.0%	0.0%	0.1%	0.0%	0.1%	0.1%	0.1%	0.0%
FCF Margin %	-1.3%	-	-	-	-	-	5.4%	5.8%	6.5%	5.2%	4.9%
ROE %	0.1%	0.0%	0.1%	0.1%	0.1%	0.2%	0.1%	0.2%	0.2%	0.2%	0.2%
ROA %	0.0%	0.0%	0.0%	0.0%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%
ROIC %	7.1%	3.2%	12.2%	11.3%	11.5%	16.6%	11.7%	15.6%	9.8%	12.3%	15.4%

Key Ratio

TTM

2025

2024

2023

2022

2021

2020

2019

2018

2017

2016

Gross Margin %

0.3%

Operating Margin %

0.1%

0.0%

0.1%

EBITDA Margin %

0.1%

Net Margin %

0.0%

0.1%

0.0%

0.1%

0.0%

FCF Margin %

-1.3%

5.4%

5.8%

6.5%

5.2%

4.9%

ROE %

0.1%

0.0%

0.1%

0.2%

0.1%

0.2%

ROA %

0.0%

0.1%

ROIC %

7.1%

3.2%

12.2%

11.3%

11.5%

16.6%

11.7%

15.6%

9.8%

12.3%

15.4%

Line Item	TTM	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
	$12.9B	$12.7B	$12.3B	$12.6B	$12.4B	$10.1B	$10.0B	$9.4B	$8.9B	$11.6B	$10.6B
	—	$8.7B	$8.5B	$8.8B	$8.7B	—	—	—	—	—	—
	$4.0B	$4.0B	$3.9B	$3.8B	$3.7B	$2.8B	$3.1B	$2.9B	$2.7B	$3.2B	$3.0B
Gross Margin	31.2%	31.7%	31.3%	30.3%	29.6%	27.8%	30.9%	30.9%	30.9%	27.9%	28.3%
	—	$3.0B	$3.0B	$2.8B	$2.8B	—	—	—	—	—	—
Depreciation	—	$251M	$210M	$182M	—	$186M	$185M	$144M	$193M	$170M	$159M
Total Operating Expenses	—	$3.4B	$3.2B	$3.1B	$2.8B	—	—	—	—	—	—
	$647M	$621M	$615M	$747M	$852M	$535M	$718M	$601M	$670M	$772M	$734M
EBIT	$647M	$621M	$615M	$747M	$852M	$535M	$718M	$601M	$670M	$772M	$734M
EBITDA	$905M	$872M	$825M	$929M	$852M	$717M	$900M	$741M	$802M	$944M	$893M
Operating Margin	5.0%	4.9%	5.0%	5.9%	6.9%	5.3%	7.2%	6.4%	7.5%	6.7%	6.9%
EBITDA Margin	7.0%	6.9%	6.7%	7.3%	6.9%	7.1%	9.0%	7.9%	9.0%	8.2%	8.4%
	—	$131M	$87M	$44M	$28M	$41M	$51M	$76M	$51M	$32M	$26M
	—	$513M	$542M	$721M	$831M	—	—	—	—	—	—
Income Tax Expense	—	$128M	$120M	$170M	$197M	$95M	$160M	$107M	$309M	$218M	$211M
	$415M	$398M	$436M	$566M	$661M	$419M	$719M	$562M	$459M	$556M	$523M
Net Margin	3.2%	3.1%	3.5%	4.5%	5.3%	4.2%	7.2%	6.0%	5.2%	4.8%	4.9%
	$0.84	$3.07	$3.18	$3.95	$4.51	$2.83	$4.70	$3.51	$2.59	$6.27	$5.78
Diluted EPS	$0.84	$3.05	$3.16	$3.91	$4.45	$2.83	$4.70	$3.51	$2.59	$6.27	$5.78
Weighted Avg Basic	—	127M	131M	136M	140M	—	—	—	—	—	—
Weighted Avg Diluted	—	128M	132M	138M	142M	—	—	—	—	—	—

Line Item

TTM

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

$12.9B

$12.7B

$12.3B

$12.6B

$12.4B

$10.1B

$10.0B

$9.4B

$8.9B

$11.6B

$10.6B

—

$8.7B

$8.5B

$8.8B

$8.7B

—

$4.0B

$3.9B

$3.8B

$3.7B

$2.8B

$3.1B

$2.9B

$2.7B

$3.2B

$3.0B

Gross Margin

31.2%

31.7%

31.3%

30.3%

29.6%

27.8%

30.9%

27.9%

28.3%

—

$3.0B

$2.8B

—

Depreciation

—

$251M

$210M

$182M

—

$186M

$185M

$144M

$193M

$170M

$159M

Total Operating Expenses

—

$3.4B

$3.2B

$3.1B

$2.8B

—

$647M

$621M

$615M

$747M

$852M

$535M

$718M

$601M

$670M

$772M

$734M

EBIT

$647M

$621M

$615M

$747M

$852M

$535M

$718M

$601M

$670M

$772M

$734M

EBITDA

$905M

$872M

$825M

$929M

$852M

$717M

$900M

$741M

$802M

$944M

$893M

Operating Margin

5.0%

4.9%

5.0%

5.9%

6.9%

5.3%

7.2%

6.4%

7.5%

6.7%

6.9%

EBITDA Margin

7.0%

6.9%

6.7%

7.3%

6.9%

7.1%

9.0%

7.9%

9.0%

8.2%

8.4%

—

$131M

$87M

$44M

$28M

$41M

$51M

$76M

$51M

$32M

$26M

—

$513M

$542M

$721M

$831M

—

Income Tax Expense

—

$128M

$120M

$170M

$197M

$95M

$160M

$107M

$309M

$218M

$211M

$415M

$398M

$436M

$566M

$661M

$419M

$719M

$562M

$459M

$556M

$523M

Net Margin

3.2%

3.1%

3.5%

4.5%

5.3%

4.2%

7.2%

6.0%

5.2%

4.8%

4.9%

$0.84

$3.07

$3.18

$3.95

$4.51

$2.83

$4.70

$3.51

$2.59

$6.27

$5.78

Diluted EPS

$0.84

$3.05

$3.16

$3.91

$4.45

$2.83

$4.70

$3.51

$2.59

$6.27

$5.78

Weighted Avg Basic

—

127M

131M

136M

140M

—

Weighted Avg Diluted

—

128M

132M

138M

142M

—

HENRY SCHEIN INC (HSIC) Stock Analysis — April 2026 Rating, Price, and Forecast

Last updated: April 2026

Company Overview — What Does HENRY SCHEIN INC Do?

Henry Schein, Inc. provides health care products and services to dental practitioners and laboratories, physician practices, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services. The Health Care Distribution segment offers dental products, including infection-control products, handpieces, preventatives, impression materials, composites, anesthetics, teeth, dental implants, gypsum, acrylics, articulators, abrasives, dental chairs, delivery units and lights, X-ray supplies and equipment, personal protective equipment, and high-tech and digital restoration equipment, as well as equipment repair services. This segment also provides medical products comprising branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, X-ray products, equipment, and vitamins. The Technology and Value-Added Services segment offers software, technology, and other value-added services that include practice management software systems for dental and medical practitioners. This segment also provides value-added practice solutions, which comprise financial services on a non-recourse basis, e-services, practice technology, network, and hardware services, as well as continuing education services for practitioners, and consulting and other services. Henry Schein, Inc. was founded in 1932 and is headquartered in Melville, New York. HENRY SCHEIN INC (HSIC) is classified as a mid-cap stock in the Consumer Staples sector, specifically within the Wholesale industry. The company is led by CEO Stanley M. Bergman and employs approximately 22,000 people, headquartered in Melville, New York. With a market capitalization of $8.4B, HSIC is one of the notable companies in the Consumer Staples sector.

HENRY SCHEIN INC (HSIC) Stock Rating — Hold (April 2026)

As of April 2026, HENRY SCHEIN INC receives a Hold rating with a composite score of 47.4/100 and 3 out of 5 stars from the Blank Capital Research quantitative model.HSIC ranks #1,458 out of 4,446 stocks in our coverage universe. Within the Consumer Staples sector, HENRY SCHEIN INC ranks #51 of 180 stocks, placing it in the upper half of its Consumer Staples peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

HSIC Stock Price and 52-Week Range

HENRY SCHEIN INC (HSIC) currently trades at $75.34. The stock lost $0.28 (0.4%) in the most recent trading session. The 52-week high for HSIC is $89.29, which means the stock is currently trading -15.6% from its annual peak. The 52-week low is $60.56, putting the stock 24.4% above its annual trough. Recent trading volume was 874K shares, suggesting relatively thin trading activity.

Is HSIC Overvalued or Undervalued? — Valuation Analysis

HENRY SCHEIN INC (HSIC) carries a value factor score of 48/100 in the Blank Capital model, indicating fair valuation relative to historical norms. The trailing price-to-earnings ratio is 20.41x, compared to the Consumer Staples sector average of 33.11x — a discount of 38%. The price-to-book ratio stands at 2.11x, versus the sector average of 1.74x. The price-to-sales ratio is 0.66x, compared to 0.35x for the average Consumer Staples stock. On an enterprise value basis, HSIC trades at 9.36x EV/EBITDA, versus 6.93x for the sector.

Overall, HSIC's valuation appears roughly in line with sector benchmarks, suggesting the market is pricing the stock fairly given its current fundamentals and growth trajectory. Neither deep value nor significantly overpriced, the stock occupies a middle ground on valuation.

HENRY SCHEIN INC Profitability — ROE, Margins, and Quality Score

HENRY SCHEIN INC (HSIC) earns a quality factor score of 50/100, indicating solid business quality with consistent operational execution. The return on equity (ROE) is 10.3%, compared to the Consumer Staples sector average of 7.7%, which is within a healthy range. Return on assets (ROA) comes in at 3.7% versus the sector average of 3.1%.

On a margin basis, HENRY SCHEIN INC reports gross margins of 31.2%, compared to 26.2% for the sector. The operating margin is 5.0% (sector: 2.9%). Net profit margin stands at 3.2%, versus 1.6% for the average Consumer Staples stock. Revenue growth is running at 6.5% on a trailing basis, compared to 3.1% for the sector. The overall profitability profile is adequate, though there may be room for margin expansion.

HSIC Debt, Balance Sheet, and Financial Health

HENRY SCHEIN INC has a debt-to-equity ratio of 154.0%, compared to the Consumer Staples sector average of 72.0%. This elevated leverage warrants close monitoring, as it increases the company's sensitivity to rising interest rates and economic downturns. The current ratio is 1.40x, suggesting adequate working capital coverage. Total debt on the balance sheet is $3.36B. Cash and equivalents stand at $136M.

HSIC has a beta of 0.64, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for HENRY SCHEIN INC is 83/100, indicating low-volatility characteristics and consistent price behavior that appeals to risk-averse investors.

HENRY SCHEIN INC Revenue and Earnings History — Quarterly Trend

In TTM 2026, HENRY SCHEIN INC reported revenue of $12.92B and earnings per share (EPS) of $0.84. Net income for the quarter was $415M. Gross margin was 31.2%. Operating income came in at $647M.

In Q3 2025, HENRY SCHEIN INC reported revenue of $3.34B and earnings per share (EPS) of $0.84. Net income for the quarter was $109M. Gross margin was 30.7%. Revenue grew 5.2% year-over-year compared to Q3 2024. Operating income came in at $164M.

In Q2 2025, HENRY SCHEIN INC reported revenue of $3.24B and earnings per share (EPS) of $0.71. Net income for the quarter was $94M. Gross margin was 31.4%. Revenue grew 3.3% year-over-year compared to Q2 2024. Operating income came in at $151M.

In Q1 2025, HENRY SCHEIN INC reported revenue of $3.17B and earnings per share (EPS) of $0.89. Net income for the quarter was $113M. Gross margin was 31.6%. Revenue grew -0.1% year-over-year compared to Q1 2024. Operating income came in at $175M.

Over the past 8 quarters, HENRY SCHEIN INC has demonstrated a growth trajectory, with revenue expanding from $3.17B to $12.92B. Investors analyzing HSIC stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

HSIC Dividend Yield and Income Analysis

HENRY SCHEIN INC (HSIC) does not currently pay a dividend. This is common among smaller companies in the Wholesale industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Consumer Staples dividend stocks may want to explore other Consumer Staples stocks or use the stock screener to filter by dividend yield.

HSIC Momentum and Technical Analysis Profile

HENRY SCHEIN INC (HSIC) has a momentum factor score of 49/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 31/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 16/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

HSIC vs Competitors — Consumer Staples Sector Ranking and Peer Comparison

Within the Consumer Staples sector, HENRY SCHEIN INC (HSIC) ranks #51 out of 180 stocks based on the Blank Capital composite score. This places HSIC in the upper half of all Consumer Staples stocks in our coverage universe. Key competitors and sector peers include Ituran Location & Control Ltd. (ITRN) with a score of 60.3/100, DARLING INGREDIENTS INC. (DAR) with a score of 52.9/100, Bunge Global SA (BG) with a score of 53.0/100, SANFILIPPO JOHN B & SON INC (JBSS) with a score of 54.1/100, and Archer-Daniels-Midland Co (ADM) with a score of 52.2/100.

Comparing HSIC against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full HSIC vs S&P 500 (SPY) comparison to assess how HENRY SCHEIN INC stacks up against the broader market across all factor dimensions.

HSIC Next Earnings Date

No upcoming earnings date has been announced for HENRY SCHEIN INC (HSIC) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy HSIC? — Investment Thesis Summary

HENRY SCHEIN INC presents a balanced picture with arguments on both sides. Low volatility (stability score 83/100) reduces downside risk.

In summary, HENRY SCHEIN INC (HSIC) earns a Hold rating with a composite score of 47.4/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on HSIC stock.

Related Resources for HSIC Investors

Explore more research and tools: HSIC vs S&P 500 comparison, top Consumer Staples stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare HSIC head-to-head with peers: HSIC vs ITRN, HSIC vs DAR, HSIC vs BG.

Business quality

Valuation edge

Market alpha

Unlock Investment Thesis

Unlock Performance & Technicals

Unlock Valuation Tools

Institutional peer matrix

Dispersion: efficiency vs. valuation

Lateral intelligence network

Unlock Financial Statements

Unlock Ownership & Management

Intelligence Feed

Henry Schein to Reduce Size of the Board of Directors following 2026 Annual Meeting of Stockholders

Dental Equipment & Technology Stocks Q4 Recap: Benchmarking Align Technology (NASDAQ:ALGN)

3 Healthcare Stocks with Open Questions

1 S&P 500 Stock for Long-Term Investors and 2 We Brush Off

Why Henry Schein (HSIC) is a Top Value Stock for the Long-Term

Unlock Earnings Transcripts

Institutional Intelligence FAQ

Related Research & Tools

Related Consumer Staples Stocks

HENRY SCHEIN INC (HSIC) Stock Analysis — April 2026 Rating, Price, and Forecast

Company Overview — What Does HENRY SCHEIN INC Do?

HENRY SCHEIN INC (HSIC) Stock Rating — Hold (April 2026)

HSIC Stock Price and 52-Week Range

Is HSIC Overvalued or Undervalued? — Valuation Analysis

HENRY SCHEIN INC Profitability — ROE, Margins, and Quality Score

HSIC Debt, Balance Sheet, and Financial Health

HENRY SCHEIN INC Revenue and Earnings History — Quarterly Trend

HSIC Dividend Yield and Income Analysis

HSIC Momentum and Technical Analysis Profile

HSIC vs Competitors — Consumer Staples Sector Ranking and Peer Comparison

HSIC Next Earnings Date

Should You Buy HSIC? — Investment Thesis Summary

Related Resources for HSIC Investors

Comments

Institutional Benchmarks

Get alerted on rating changes

Intelligence Feed

Henry Schein to Reduce Size of the Board of Directors following 2026 Annual Meeting of Stockholders

Dental Equipment & Technology Stocks Q4 Recap: Benchmarking Align Technology (NASDAQ:ALGN)

3 Healthcare Stocks with Open Questions

1 S&P 500 Stock for Long-Term Investors and 2 We Brush Off

Why Henry Schein (HSIC) is a Top Value Stock for the Long-Term